Metagenics has announced the appointment of Patrick Sly as CEO, effective immediately. Sly is a seasoned executive in the health and wellness industry.

Outgoing president and CEO Pat Smallcombe, who led Metagenics through a period of substantial growth beginning in 2023, will transition to the role of co-chair of the board.

“With Patrick’s deep experience in medical nutrition, partnerships with healthcare professionals, and leadership of global businesses, I couldn’t imagine a stronger candidate to succeed Pat Smallcombe’s successful tenure. Patrick’s leadership style focuses on integrity, innovation, and collaboration, an ideal fit for Metagenics’ culture,” said Ryan Fagan, deal partner in the consumer group of Gryphon Investors, the middle-market private firm backing the brand.

Sly has led the growth of several large consumer health and nutrition businesses. Most recently, he served as global president of Reckitt’s $8 billion consumer health division, and previously served as global president of Reckitt’s $3 billion nutrition business.

Sly has lived in five countries, and brings a high level of cultural fluency, adaptability, and global strategic insight, the company reported, and he brings “deep category expertise, crisis-tested leadership, and a passion for building inclusive, high-performance cultures.”

Sly earned an MBA from Washington University in St. Louis’ Olin Business School and a Bachelor of Science in Business from Indiana University’s Kelley School of Business.

“I’m thrilled to be joining Metagenics at such an exciting time,” said Sly. “The professional segment of the supplements category has tremendous growth potential, and Metagenics’ outstanding brand and clinically tested product line position the company for continued success. I’m especially impressed by the very strong team and solid foundation that Pat Smallcombe has built, and I look forward to working with the organization to drive the next phase of growth.”